Details of the Drug
General Information of Drug (ID: DMKEX7O)
| Drug Name |
Plecanatide
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | Trulance | ||||||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||||||
| Affected Organisms |
Humans and other mammals
|
||||||||||||||||||||||||||
| ATC Code | |||||||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||||||
| 3D MOL is unavailable | 2D MOL | ||||||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 5 | Molecular Weight (mw) | 1681.9 | |||||||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -8.2 | ||||||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 28 | ||||||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 23 | ||||||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 31 | ||||||||||||||||||||||||||
| ADMET Property | |||||||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | ||||||||||||||||||||||||||
| Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | ||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| ICD Disease Classification | 13 Disease of the digestive system | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease Class | ICD-11: DD91 Irritable bowel syndrome | |||||||||||||||||
| The Studied Tissue | Rectal colon tissue | |||||||||||||||||
| The Studied Disease | Irritable bowel syndrome [ICD-11:DD91.0] | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
| 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018 | ||||
|---|---|---|---|---|---|
| 2 | 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. | ||||
| 3 | The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu Rev Pharmacol Toxicol. 2014;54:9-26. | ||||
| 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||


